Studying genetic factors in familial non-medullary thyroid cancer
Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer
This study is trying to find out how genetics play a role in familial non-medullary thyroid cancer to help identify family members who might be at risk and improve early diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 7 Years to 90 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT01109420 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on familial non-medullary thyroid cancer (FNMTC) to understand its natural history and identify genetic susceptibility factors. Researchers will evaluate individuals with a family history of FNMTC to develop effective screening strategies and quantify cancer risks among family members. Participants will be assessed through family history, physical examinations, and other evaluations over time. The goal is to enhance early diagnosis and treatment options for those at risk.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 7 and older with a family history of non-medullary thyroid cancer, specifically those with two first-degree relatives affected by the disease.
Not a fit: Patients without a family history of non-medullary thyroid cancer or those who do not meet the eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and early detection of familial non-medullary thyroid cancer, ultimately enhancing patient outcomes.
How similar studies have performed: While there is ongoing research in familial thyroid cancers, this specific approach to studying genetic susceptibility in FNMTC is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Subjects will be selected for this protocol based on either a clinical diagnosis of non-medullary thyroid cancer and the presence of one family member with the disease or the presence of 2 living family members with this disease. Patient selection for this protocol will not be based on gender, race, or ethnic background. In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Adults or minor (\>= 7 years+), males and females. * An unaffected individual with (Bullet) 2 first-degree relatives who have or have had nonmedullary thyroid cancer OR -An affected individual with documented diagnosis of non-medullary thyroid cancer and (Bullet) one living relative with documented non-medullary thyroid cancer (Note: as this is a familial study, subjects do not need to present with the disease) OR * Any member of an affected family. (Note: for this study, an affected family is defined as a family having 2 or more 1st degree relatives with a documented diagnosis of FNMTC.) * Adults must be able to understand and the willingness to sign the informed consent document. * Adults must be able to complete the family history questionnaire. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be not be allowed to enroll in this study: -Subjects unwilling/unable to give informed consent.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Joanna Klubo-Gwiezdzinska, M.D. — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study coordinator: Padmasree Veeraraghavan, R.N.
- Email: ncieobinquiry@mail.nih.gov
- Phone: (301) 451-7710
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.